Middle Eastern distributor opens new office in prominent Dubai Healthcare City complex in Dubai
Generex Biotechnology Corporation (NasdaqCM: GNBT), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today that it will be participating at the upcoming 2008 Arab Health Congress (www.arabhealthonline.com). The Arab Health Congress will be held between January 28 - 31 at the Dubai International Exhibition Centre in Dubai, United Arab Emirates.
The Arab Health Congress is touted as the region's premier event for the Middle East bringing healthcare manufacturers, wholesalers, dealers and distributors together with some of the most important and influential decision-makers in the Arab world. This year's Arab Health Congress will showcase products and services by more than 2200 exhibitors representing over 65 countries and attracting more than 50,000 healthcare professionals from all over the world.
The Company will be sharing a booth with its Middle Eastern Master Distributor, Leosons General Trading. Leosons recently established a new pharmaceutical company in the region by the name of MedPro LLC in collaboration with H.E. Sheikh Saeed Bin Obaid Al Maktoum, a member of the Royal Family of the United Arab Emirates. MedPro LLC held its open house recently at its offices located within the Dubai Healthcare City complex (www.dhcc.ae). MedPro's mission is to establish itself as a company that services the needs of patients living with chronic illnesses, such as diabetes, in order to improve the quality of life for individuals who need to address their health challenges utilizing compliance-focused treatments.
Generex and Leosons welcome all participants attending the Arab Health Congress to visit booth number RC 21 in order to learn more about the Generex product pipeline.
About Leosons
Leosons is a 25-year old private multinational operating company in the Middle East focusing on the pharmaceutical and healthcare industry. Leosons distributes 15 healthcare-related products which are considered category leaders.
About Generex
Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device. The Company's flagship product, oral insulin (Generex Oral-lyn™), which is available for sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes and which was approved for sale in India in October 2007, is in various stages of clinical development around the world. For more information, visit the Generex website at www.generex.com.
Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain ``forward-looking statements'' within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as ``expects,'' ``plans,'' ``intends,'' ``believes,'' ``will,'' ``estimates,'' ``forecasts,'' ``projects'' or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any ``phase'' of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.
Search News
